Search

Learn about kratom, an herbal product that some believe acts as a painkiller and could help those with cancer.

… Wednesday, August 8, 2018 Summary MSK experts say we don’t yet have enough information about kratom to know whether it is safe and effective for people with cancer. In the past few years, a number of companies in the United States have begun selling an herbal product called kratom, mostly online. The

A team of scientists is combining sophisticated chemistry and experiments in zebrafish to develop a new cancer drug that shows early potential against melanoma and metastatic breast cancer.

… Monday, June 22, 2015 Summary A growing community of Memorial Sloan Kettering scientists are doing research into  epigenetics  — an intricate system of biochemical adjustments that cells use to regulate genes — to improve our understanding of cancer and other diseases. One of these researchers is Mingkui

A visionary program investigates how the body’s ecosystem affects cancer.

… Friday, April 1, 2022 Dear MSK Community,   We are poised at a pivotal moment in cancer research.   For the past few decades, researchers have focused on identifying gene mutations associated with cancer and have developed highly effective drugs to target them. This revolutionary approach, called precision

Temozolomide chemotherapy reduced seizures in 90 percent of patients with World Health Organization (WHO) grade 2 oligodendroglioma and tumor-related epilepsy.

… Friday, June 28, 2019 Temozolomide chemotherapy reduced seizures in 90 percent of patients with World Health Organization (WHO) grade 2 oligodendroglioma and tumor-related epilepsy, according to the results of a recent retrospective study of 39 patients treated at Memorial Sloan Kettering Cancer Center

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

… Tuesday, January 15, 2019 Summary The biggest study of its kind in North America finds a watch-and-wait strategy can have excellent long-term results for some people with rectal cancer. Cancers of the colon and rectum are often grouped together as colorectal cancer because both are part of the large

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.

… Wednesday, June 23, 2021 From amoebas to zebras, all living things evolve. They change over time as pressures from the environment cause individuals with certain traits to become more common in a population while those with other traits become less common. Cancer is no different. Within a growing tumor

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

… Thursday, January 31, 2019 Summary One of the most common immunotherapy side effects is gastrointestinal distress. MSK gastroenterologist David Faleck explains why this happens and how to find relief. Chances are that you have heard some buzz about immunotherapy . This type of cancer treatment trains

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered